Zoledronic Acid as a Therapeutic Option for Hypercalcemia in Subcutaneous Fat Necrosis: Series of Four Infants

Subcutaneous fat necrosis (SFN) of the newborn is a self-limiting condition, yet the associated hypercalcemia may result in life-threatening complications. We report a series of four term infants who developed symptomatic hypercalcemia secondary to SFN. Clinical features included firm subcutaneous nodules and elevated serum calcium levels, with suppressed parathyroid hormone (PTH) levels. Management comprises early recognition of SFN-associated hypercalcemia and prompt treatment. We hereby report the use of a single dose of zoledronic acid as an effective therapy for the resolution of hypercalcemia.